Bio-hybrid device acts as 'thermostat' to control systemic inflammation in sepsis

May 14, 2012

A small, external bioreactor holding human cells pumped out an anti-inflammatory protein to prevent organ damage and other complications in a rat with acute inflammation caused by bacterial products in a model of sepsis, according to a report from researchers at the University of Pittsburgh School of Medicine and the McGowan Institute for Regenerative Medicine. The findings were published today in the inaugural issue of Disruptive Science and Technology.

Inflammation is a necessary that brings cells and proteins to the site of tissue injury to contend with foreign agents, such as bacteria and the products they produce, and to begin the healing process, explained senior author Yoram Vodovotz, Ph.D., professor, Department of Surgery, and director, Center for Inflammation and Regenerative Modeling at the McGowan Institute. But sometimes, the inflammatory response escalates to create damage on its own, triggering more inflammation in a self-sustaining and dangerous cycle.

"In sepsis, for example, the inflammatory response evolves almost too quickly, but the available treatment strategies aim to prevent inflammation entirely," he said. "A better approach would be to turn down the response when it's too strong, yet still have appropriate inflammation signaling to promote tissue repair."

During inflammation, the body makes a protein called tumor necrosis factor-alpha, or TNF-α. It also makes its counterpart, soluble TNF-α receptor, or sTNFR, which binds to and reduces the level of TNF-α. In some situations, such as sepsis, not enough sTNFR is made to limit the .

Dr. Vodovotz and his team loaded a small bioreactor with human liver cells engineered to make sTNFR continuously. Through an intravenous line, blood from an anesthetized rat experiencing acute but transient inflammation was pumped through the bioreactor, exposing it to the engineered cells.

When the was loaded with sTNFR-producing cells, sTNFR levels rose beyond what the animal could produce on its own, while TNF-α levels dropped, as did other markers of inflammation. The animal's blood pressure also improved, and markers of were reduced.

"This bio-hybrid device acts as a kind of inflammation thermostat," Dr. Vodovotz said. "By loading it with cells that produce different amounts of sTNFR, or other inflammatory blockers, we may soon be able to tailor our interventions to carefully balance inflammation and immune responses based on the patient's medical situation."

His team now is exploring the effectiveness of cells engineered to produce sTNFR based on the individual production of TNF-α, rather than continuously, in order to create a disease-specific response for each patient. Such a personalized medicine therapy platform could be extended based on emerging knowledge regarding the biology of inflammation.

The Vodovotz group also is creating computer models of inflammation, which could be used to engineer the next generation of this device. The portability of the device could be particularly useful on the battlefield, where early intervention to control systemic inflammation after injury might improve the chances of survival.

Explore further: Stem cells from bone marrow save the day

Related Stories

Stem cells from bone marrow save the day

May 13, 2011
New research, published in BioMed Central's open access journal Stem Cell Research & Therapy, investigates the therapeutic use of human stem cells from bone marrow against acute lung injury and identifies TNF-α-induced ...

Scientists identify cell death pathway involved in lethal sepsis

December 22, 2011
Sepsis, a form of systemic inflammation, is the leading cause of death in critically ill patients. Sepsis is linked with massive cell death; however, the specific mechanisms involved in the lethality of sepsis are unclear. ...

Alcohol impairs the body's ability to fight off viral infection

September 30, 2011
Alcohol is known to worsen the effects of disease, resulting in longer recovery period after trauma, injury or burns. It is also known to impair the anti-viral immune response, especially in the liver, including response ...

Recommended for you

Breathing exercises help asthma patients with quality of life

December 13, 2017
A study led by the University of Southampton has found that people who continue to get problems from their asthma, despite receiving standard treatment, experience an improved quality of life when they are taught breathing ...

Study highlights the need for research into prevention of inflammatory bowel disease

December 7, 2017
Countries in Africa, Asia, the Middle East and South America have seen a rise in incidence of inflammatory bowel disease as they have become increasingly industrialised and westernised, a new study has found.

Air pollution can increase asthma risk in adults, even at low levels

November 24, 2017
Living close to a busy road can be bad for your respiratory health if you are middle aged, new Australian research has found.

Evidence found of oral bacteria contributing to bowel disorders

October 20, 2017
(Medical Xpress)—An international team of researchers has found evidence that suggests certain types of oral bacteria may cause or exacerbate bowel disorders. In their paper published in the journal Science, the group describes ...

New compound discovered in fight against inflammatory disease

September 22, 2017
A 10-year study by University of Manchester scientists for a new chemical compound that is able to block a key component in inflammatory illness has ended in success.

Asthma researchers test substance from coralberry leaves

September 14, 2017
The coralberry could offer new hope for asthmatics. Researchers at the University of Bonn have extracted an active pharmaceutical ingredient from its leaves to combat asthma, a widespread respiratory disease. In mice, it ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.